News
MyChesCo on MSN17h
Johnson & Johnson Seeks FDA Nod for TREMFYA® Label Update Following Psoriatic Arthritis Trial Success
HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) has submitted a supplemental Biologics License Application (sBLA) to the U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback